INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 78 filers reported holding INOZYME PHARMA INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,353,974 | +148.2% | 2,465,232 | +229.2% | 0.00% | – |
| Q2 2023 | $4,171,005 | -48.2% | 748,834 | -46.7% | 0.00% | – |
| Q1 2023 | $8,056,334 | +393.3% | 1,405,992 | +130.7% | 0.00% | – |
| Q3 2022 | $1,633,000 | -43.9% | 609,380 | -0.1% | 0.00% | – |
| Q2 2022 | $2,909,000 | +16.7% | 609,819 | +0.0% | 0.00% | – |
| Q1 2022 | $2,493,000 | -40.0% | 609,594 | +0.0% | 0.00% | – |
| Q4 2021 | $4,156,000 | -41.2% | 609,380 | 0.0% | 0.00% | -100.0% |
| Q3 2021 | $7,063,000 | -32.0% | 609,380 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $10,384,000 | -13.9% | 609,380 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $12,066,000 | -4.1% | 609,380 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $12,578,000 | -21.5% | 609,380 | 0.0% | 0.00% | -50.0% |
| Q3 2020 | $16,021,000 | – | 609,380 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 4,494,851 | $18,878,374 | 7.53% |
| CHI Advisors LLC | 1,270,027 | $5,334,112 | 2.11% |
| Samsara BioCapital, LLC | 1,562,500 | $6,562,500 | 2.01% |
| Affinity Asset Advisors, LLC | 1,379,852 | $5,795,378 | 1.63% |
| Sofinnova Investments, Inc. | 4,280,308 | $17,977,294 | 1.13% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,234,907 | $5,186,609 | 0.94% |
| Octagon Capital Advisors LP | 1,300,000 | $5,460,000 | 0.84% |
| NEA Management Company, LLC | 2,437,689 | $10,238,294 | 0.79% |
| Knott David M Jr | 454,008 | $1,907 | 0.73% |
| Rock Springs Capital Management LP | 3,681,174 | $15,460,931 | 0.41% |